Key Takeaways:
-
Iksuda’s PermaLink technology can design ADCs insusceptible to drug de-conjugation.
Iksuda Therapeutics is on mission to design and develop more securely conjugated and efficacious antibody-drug conjugates (ADCs) for the treatment of cancers and is taking a liberated approach to using technology.
The UK firm’s story goes back to 2007 when investor IP Group founded a company called Glythera with two platforms...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?